MiNK Therapeutics, Inc. (INKT)
| Market Cap | 58.32M -19.3% |
| Revenue (ttm) | n/a |
| Net Income | -11.36M |
| EPS | -2.40 |
| Shares Out | 5.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,949 |
| Open | 11.33 |
| Previous Close | 11.68 |
| Day's Range | 11.06 - 11.45 |
| 52-Week Range | 8.48 - 16.98 |
| Beta | 0.48 |
| Analysts | Strong Buy |
| Price Target | 39.00 (+241.26%) |
| Earnings Date | Aug 13, 2026 |
About INKT
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients wit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for INKT stock is "Strong Buy." The 12-month stock price target is $39.0, which is an increase of 241.26% from the latest price.
News
MiNK Therapeutics Earnings Call Transcript: Q2 2026
Advanced a phase II trial for agenT-797 in ARDS, showing early positive patient outcomes and expanding global access through a paid program in Brazil. Cash position remains stable, with disciplined spending and external funding supporting ongoing trials.
MiNK Therapeutics Earnings release: Q2 2026
MiNK Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
MiNK Therapeutics Quarterly report: Q2 2026
MiNK Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT) cel...
MiNK Therapeutics presents early observations from Phase 2 agenT-797 trial
MiNK Therapeutics (INKT) announced initial observations from patients treated with agenT-797 in its ongoing Phase 2 study in patients with severe hypoxemic pneumonia. The observations were presented a...
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to...
MiNK Therapeutics Transcript: AGM 2026
The meeting approved the election of directors and auditor, confirmed a quorum, and outlined a strategy focused on immune restoration across diseases. Key initiatives include advancing clinical trials in ARDS, expanding global access, and securing external funding for new therapies.
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) ce...
MiNK Therapeutics doses first patient in agenT-797 trial
MiNK Therapeutics (INKT) announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 with standard of care vs. placebo with SOC in patients…
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for ca...
MiNK Therapeutics reports new data on agenT-797 at ATS 2026
MiNK Therapeutics (INKT) announced new clinical and translational data presented at the American Thoracic Society International Conference 2026 and the simultaneous publication in Clinical Immunology ...
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapie...
MiNK Therapeutics Earnings Call Transcript: Q1 2026
New clinical data show iNKT cell therapy's promise in cancer and ARDS, with a pivotal phase II trial underway and regulatory clearance in the US and Ukraine. Cash runway supports operations for 12 months, and partnerships expand platform reach.
MiNK Therapeutics Earnings release: Q1 2026
MiNK Therapeutics released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
MiNK Therapeutics Quarterly report: Q1 2026
MiNK Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026 AACR and ASGCT presentations showcase d...
MiNK Therapeutics initiates agenT-797 clinical trial
MiNK Therapeutics (INKT) and First Lviv Territorial Medical Union announced the initiation of a randomized Phase 2 clinical trial evaluating agenT-797, MiNK’s off-the-shelf allogeneic invariant natura...
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
NEW YORK and LVIV, Ukraine, May 14, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune...
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies for...
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to ...
MiNK Therapeutics Proxy statement: Proxy filing
MiNK Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
MiNK Therapeutics management to meet virtually with B. Riley
Virtual Meeting to be held on April 23-24 and on April 27 hosted by B. Riley.
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therap...
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therap...
MiNK Therapeutics Earnings Call Transcript: Q4 2025
Advanced cell therapy platform showed durable survival in solid tumors and promising results in ARDS and GVHD, supported by increased cash reserves and non-dilutive funding. Key randomized trials and data readouts are expected in 2026.